Monday, May 9, 2022

Aspen Neuroscience Scores $147.5M More

San Diego-based biotech startup Aspen Neuroscience said this morning that it has raised $147.5M in a Series B funding round. The company--which is working on treatments for Parkinson's disease--said the funding was co-led by GV, LYFE Capital and Revelation Partners, and also included new investors Newton Investment Management, EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment and others, plus existing investors OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture Investments. As part of the financing, Doug Fisher of Revelation Partners will join the company's board of directors.